Chemotherapy in Elderly Patients with Colorectal Cancer

CME Activity Information
Release Date:	April 30, 2008
Most Recent Review:	April 30, 2008*
Most Recent Update:	April 30, 2008
Date Credit Expires:	April 30, 2010
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by April 30, 2010, in order to receive the credit or participation certificate.

1. Evaluate elderly CRC patients with regard to overall health, independence, and performance status using a comprehensive geriatric assessment.
2. Assess the determinants for response to treatment and overall survival in elderly CRC patients who can be categorized as either fit, intermediate, or frail.
3. Determine the optimal first-line chemotherapy regimen for the fit elderly polymedicated patient with CRC.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://cme.theoncologist.com/misc/edboard.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All activity planners, authors, and reviewers are required to submit conflict of interest forms. These forms accompany the activity through the peer review process. Any reviewers who have a conflict of interest are recused. When a reviewer is recused, other suitable reviewers with no self-reported conflicts of interests are selected to conduct the reviews. Editors’ disclosures are published annually online, whereas reviewers’ disclosures are held in confidence within the Editorial Office. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Professor, Klinik für Onkologie/Hämatologie, Klinikum Oldenburg, Oldenburg, Germany.
Disclosures: The author has indicated no relevant commercial relationships.

Gunnar Folprecht, M.D.

Credentials: Senior Consultant, Outpatient Unit, Department of Medical Oncology, University Hospital “Carl Gustav Carus,” Medical Department I, Dresden, Germany.
Disclosures: The author has received compensation from Merck KGaA, Pfizer, and Sanofi-Aventis, and has contracted research from Merck KGaA and Pfizer.

Richard M. Goldberg, M.D.

Credentials: Professor and Chief of Hematology and Oncology, Physician in Chief of the North Carolina Cancer Hospital, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Disclosures: The author has acted as a consultant to and received honoraria from AstraZeneca, Bochringer Ingelheim, Bristol-Myers Squibb, Genentech, ImClone, Pfizer, Sanofi-Aventis, Taiho, and Yakult Honsha.

Emmanuel Mitry, M.D.

Credentials: Professor, Hôpital Amboise Paré, Paris, France.
Disclosures: The author has acted as a consultant to Pfizer and Roche.

Philippe Rougier, M.D.

Credentials: Hôpital Amboise Paré, Paris, France.
Disclosures: The author has acted as a consultant to Pfizer, Sanofi-Aventis, and Merck.

• Take this course